Content Hub

MYTX-011, an investigational ADC, enhances anti-tumor activity across patients with a wider spectrum of cMET expression levels, including those with lower to moderate expression. This ADC promotes better internalization and cytotoxicity with an extended pharmacokinetic profile and a reduced side-effect profile, showing robust activity in preclinical models. Brian Fiske, Ph.D., will be discussing the development of MYTX-011, an investigational ADC targeting cMET with enhanced activity against tumors expressing low to moderate levels of this receptor.

Chain exchange enables the development of ADC matrices by varying binders, formats, attachment positions, and payloads. This flexibility helps in optimizing ADC function, revealing that format selection can significantly impact efficacy and specificity, similar to bispecific antibodies. Ulrich Brinkmann, will be exploring how chain exchange technology is advancing ADC development by enabling the creation of matrices combining various binders, payloads, and formats.

Dual-payload ADCs like those developed by Hummingbird Bioscience combat resistance by deploying two cytotoxic agents in a single molecule, targeting cancer cells more effectively, even in resistant models. This approach enhances the therapeutic window while maintaining tolerability. Jerome Boyd-Kirkup, Ph.D., will be presenting Hummingbird Bioscience's dual-payload ADC platform, which addresses payload resistance, a common challenge in cancer therapies.

The CAPAC platform selectively activates ADC payloads at the tumor site, reducing systemic toxicity. This innovation represents a significant advance for ADCs by enhancing therapeutic index and improving patient safety profiles. José M. Mejía Oneto, M.D., Ph.D., will be talking on the CAPAC (Click Activated Protodrugs Against Cancer) platform, which activates ADCs at the tumor site using click chemistry.

Research into radioimmunotherapy potentiation includes strategies such as combination therapies and antibody modifications to improve efficacy and reduce toxicity. These enhancements aim to address the challenges of radioimmunotherapy, such as prolonged radioactivity exposure. Marika Nestor, Ph.D., will be examining potentiation strategies for radioimmunotherapy (RIT), including antibody modifications and combination therapies.

FcγR-ablated TLR7 agonist ADCs avoid FcγR binding to reduce off-target immune activation. This approach maintains effective tumor-specific immune activation while reducing immune-related side effects, with promising results in breast and pancreatic cancer models. Anqi Zhang, Ph.D. will be discussing the development of FcγR-ablated TLR7 agonist ADCs, which minimize immune side effects by bypassing Fcγ receptor interactions.

Bispecific antibodies can target two different antigens on different cell types, facilitating a stronger immune response by crosslinking these antigens and activating immune cells like T-cells. Kristel Kemper, Ph.D. (Genmab, The Netherlands) will explain how DuoBody-EpCAMx4-1BB works by targeting EpCAM on tumour cells and 4-1BB on immune cells. By crosslinking these two antigens, it enhances T-cell activation and boosts antitumor responses, which is a hallmark of bispecific antibody function

In oncology, bispecific antibodies are used to enhance immune system activation, either by engaging T-cells to target tumors or by combining multiple tumor-antigen targeting strategies for more effective cancer treatments. John Desjarlais, Ph.D. (Xencor) will talk about bispecific antibodies that engage T-cells for enhanced tumor targeting and their potential in immuno-oncology, with focus on improving the therapeutic index.

Bispecific antibodies enhance immune activation by engaging both tumour cells and immune cells simultaneously, improving T-cell responses and complement activation for a more robust immune attack against disease. Mikael Winkler, Ph.D. (Commit Biologics, Denmark) will highlight BiCE™, a platform that potentiates complement activation for more efficient immune cell killing. By using bispecific antibodies, it improves the therapeutic potential for both cancer and autoimmune diseases

Challenges in designing bispecific antibodies include selecting the right epitopes to engage both immune and target cells effectively. Advanced experimental and computational methods are used to identify and create antibodies that can activate specific immune pathways. Alexey Lugovskoy, Ph.D. (Diagonal Therapeutics) will address the difficulty in identifying effective epitopes for agonistic antibodies. By using experimental and computational techniques, bispecific antibodies targeting signaling receptors are developed to overcome these challenge

New technologies like pH-dependent biparatopic antibodies and machine learning to guide antibody design are enhancing the effectiveness and precision of bispecific and multispecific antibodies. Ryan Henrici, M.D., Ph.D. (BigHat Biosciences) will be demonstrating the use of machine learning to optimize the design of logic-gated T-cell engagers, enabling targeted tumor cell killing while sparing healthy tissue

Bispecific antibodies can be engineered to target multiple epitopes of soluble antigens in a pH-dependent manner. This allows for the formation of larger antigen-antibody complexes, which enhances the efficiency of antigen removal from the bloodstream by promoting faster cellular uptake and clearance, offering a new therapeutic avenue for diseases involving soluble antigens. Eriko Matsuda (Chugai Pharmaceutical Co. Ltd., Japan) will be discussing the use of pH-dependent biparatopic antibodies that bind to multiple epitopes of soluble antigens. This design promotes the formation of larger immune complexes, which enhances the efficiency of antigen removal from the bloodstream by accelerating cellular uptake.